177 related articles for article (PubMed ID: 34209694)
21. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17.
Petiot E; Proust A; Traversier A; Durous L; Dappozze F; Gras M; Guillard C; Balloul JM; Rosa-Calatrava M
Vaccine; 2018 May; 36(22):3101-3111. PubMed ID: 28571695
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
23. Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study.
Abdoli A; Aalizadeh R; Aminianfar H; Kianmehr Z; Teimoori A; Azimi E; Emamipour N; Eghtedardoost M; Siavashi V; Jamshidi H; Hosseinpour M; Taqavian M; Jalili H
Rev Med Virol; 2022 May; 32(3):e2305. PubMed ID: 34699647
[TBL] [Abstract][Full Text] [Related]
24. Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1.
Gränicher G; Coronel J; Pralow A; Marichal-Gallardo P; Wolff M; Rapp E; Karlas A; Sandig V; Genzel Y; Reichl U
Vaccine; 2019 Nov; 37(47):7019-7028. PubMed ID: 31005427
[TBL] [Abstract][Full Text] [Related]
25. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development.
Wu SC; Liu CC; Lian WC
Vaccine; 2004 Sep; 22(29-30):3858-64. PubMed ID: 15364432
[TBL] [Abstract][Full Text] [Related]
26. Rapid process development of serum-free pseudorabies virus production with the Quality by Design approach.
Nie J; Sun Y; Han F; Yang Y; Liu X; Liu C; Li Y; Bai Z
Cytotechnology; 2020 Apr; 72(2):283-293. PubMed ID: 32086694
[TBL] [Abstract][Full Text] [Related]
27. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
van Oosten L; Altenburg JJ; Fougeroux C; Geertsema C; van den End F; Evers WAC; Westphal AH; Lindhoud S; van den Berg W; Swarts DC; Deurhof L; Suhrbier A; Le TT; Torres Morales S; Myeni SK; Kikkert M; Sander AF; de Jongh WA; Dagil R; Nielsen MA; Salanti A; Søgaard M; Keijzer TMP; Weijers D; Eppink MHM; Wijffels RH; van Oers MM; Martens DE; Pijlman GP
mBio; 2021 Oct; 12(5):e0181321. PubMed ID: 34634927
[TBL] [Abstract][Full Text] [Related]
28. Enhanced production yields of rVSV-SARS-CoV-2 vaccine using Fibra-Cel
Cohen N; Simon I; Hazan O; Tal A; Tzadok H; Levin L; Girshengorn M; Mimran LC; Natan N; Baruhi T; David AB; Rosen O; Shmaya S; Borni S; Cohen N; Lupu E; Kedmi A; Zilberman O; Jayson A; Monash A; Dor E; Diamant E; Goldvaser M; Cohen-Gihon I; Israeli O; Lazar S; Shifman O; Beth-Din A; Zvi A; Oren Z; Makovitzki A; Lerer E; Mimran A; Toister E; Zichel R; Adar Y; Epstein E
Front Bioeng Biotechnol; 2024; 12():1333548. PubMed ID: 38449674
[TBL] [Abstract][Full Text] [Related]
29. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
30. An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals.
Offersgaard A; Duarte Hernandez CR; Feng S; Marichal-Gallardo P; Holmbeck K; Pihl AF; Fernandez-Antunez C; Alzua GP; Hartmann KT; Pham LV; Zhou Y; Gammeltoft KA; Fahnøe U; Schneider UV; Pedersen GK; Jensen HE; Christensen JP; Ramirez S; Bukh J; Gottwein JM
iScience; 2023 Feb; 26(2):105949. PubMed ID: 36644321
[TBL] [Abstract][Full Text] [Related]
31. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E;
Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961
[TBL] [Abstract][Full Text] [Related]
32. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19.
Jin C; Yu B; Zhang J; Wu H; Zhou X; Yao H; Liu F; Lu X; Cheng L; Jiang M; Wu N
BMC Infect Dis; 2021 Apr; 21(1):357. PubMed ID: 33863281
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin.
Kumaki Y; Wandersee MK; Smith AJ; Zhou Y; Simmons G; Nelson NM; Bailey KW; Vest ZG; Li JK; Chan PK; Smee DF; Barnard DL
Antiviral Res; 2011 Apr; 90(1):22-32. PubMed ID: 21338626
[TBL] [Abstract][Full Text] [Related]
34. Aerosol Transmission of the Pandemic SARS-CoV-2 and Influenza A Virus Was Blocked by Negative Ions.
Zhang C; Cui H; Zhang C; Chen Z; Jiang X; Liu J; Wan Z; Li J; Liu J; Gao Y; Jin N; Guo Z
Front Cell Infect Microbiol; 2022; 12():897416. PubMed ID: 35573774
[TBL] [Abstract][Full Text] [Related]
35. Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use.
Fulber JPC; Kamen AA
Viruses; 2022 May; 14(5):. PubMed ID: 35632717
[TBL] [Abstract][Full Text] [Related]
36. Optimization of Vero Cells Grown on a Polymer Fiber Carrier in a Disposable Bioreactor for Inactivated Coxsackievirus A16 Vaccine Development.
Chen K; Li C; Wang Y; Shen Z; Guo Y; Li X; Zhang Y
Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34200441
[TBL] [Abstract][Full Text] [Related]
37. Vero cell upstream bioprocess development for the production of viral vectors and vaccines.
Kiesslich S; Kamen AA
Biotechnol Adv; 2020 Nov; 44():107608. PubMed ID: 32768520
[TBL] [Abstract][Full Text] [Related]
38. Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2.
Plante KS; Dwivedi V; Plante JA; Fernandez D; Mirchandani D; Bopp N; Aguilar PV; Park JG; Tamayo PP; Delgado J; Shivanna V; Torrelles JB; Martinez-Sobrido L; Matos R; Weaver SC; Sastry KJ; Newman RA
Biomed Pharmacother; 2021 Jun; 138():111457. PubMed ID: 33721754
[TBL] [Abstract][Full Text] [Related]
39. Mouse hepatitis virus: A betacoronavirus model to study the virucidal activity of air disinfection equipment on surface contamination.
Pereira Oliveira G; Kroon EG
J Virol Methods; 2021 Nov; 297():114274. PubMed ID: 34474071
[TBL] [Abstract][Full Text] [Related]
40. Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions.
Hassanin AA; Haidar Abbas Raza S; Ahmed Ujjan J; Aysh ALrashidi A; Sitohy BM; Al-Surhanee AA; Saad AM; Mohamed Al-Hazani T; Osman Atallah O; Al Syaad KM; Ezzat Ahmed A; Swelum AA; El-Saadony MT; Sitohy MZ
Saudi J Biol Sci; 2022 Apr; 29(4):1981-1997. PubMed ID: 34924802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
